A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2005-06-01
The purpose of this study is to evaluate the safety, tolerability and efficacy of ertapenem
sodium as initial therapy for the treatment of complicated urinary tract infections,
including pyelonephritis in indian adults.
Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis
Completed
University of Michigan
Phase 4
2009-02-01
Critically ill patients in the intensive care unit often receive continuous hemodialysis to
treat their kidney failure. Ertapenem is an antibiotic often used in these patients.
Continuous dialysis may remove ertapenem, putting patients at risk for inappropriate
treatment of their infection. This study will determine how much ertapenem is removed by
continuous hemodialysis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
